艾塞利斯制药 EXEL

Michael M. Morrissey, Ph.D., has served as a director and as Exelixis' President and Chief Executive Officer since July 2010. Dr. Morrissey has held positions of increasing responsibility at Exelixis since he joined the company in February 2000, including serving as President of Research and Development from January 2007 to July 2010. From 1991 to 2000, Dr. Morrissey held several positions at Berlex Biosciences, last holding the position of Vice President, Discovery Research. Earlier in his career, Dr. Morrissey served as a Senior Scientist and Project Team Leader in Medicinal Chemistry at CIBA-Geigy Corporation. Dr. Morrissey has served as Chair of the board of directors of Vera Therapeutics, Inc., a publicly held, clinical-stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases, since April 2022. Dr. Morrissey previously served as a member of the board of directors of: XWPharma Ltd., a privately held, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics, from 2020 to 2023; and CERo Therapeutics, Inc., a privately held biopharmaceutical company focused on next-generation cell-based therapies for cancer, from January 2022 to November 2022. Dr. Morrissey is the author of numerous scientific publications in medicinal chemistry and drug discovery and an inventor on 70 issued U.S. patents and 25 additional published U.S. patent applications. Dr. Morrissey holds a B.S. (Honors) in Chemistry from the University of Wisconsin and a Ph.D. in Chemistry from Harvard University. Other Current Public Company Boards:Vera Therapeutics, Inc. (Chair), serving on the Audit Committee and the Nominating and Corporate Governance Committee.

Christopher J. Senner, has served as Executive Vice President and Chief Financial Officer (and in such capacity, as our principal financial officer and principal accounting officer, as defined under applicable securities laws) since July 2015. Prior to joining Exelixis, Mr. Senner served as Vice President, Corporate Finance for Gilead Sciences, Inc., a biopharmaceutical company, from March 2010 to July 2015, where he was accountable for controllership, tax, treasury and corporate and operational financial planning. Mr. Senner previously spent eighteen years at Wyeth, a pharmaceutical company acquired by Pfizer Inc. in 2009, in a variety of financial roles with increasing responsibility, most notably as Chief Financial Officer of Wyeth's U.S. pharmaceuticals business and the BioPharma Business Unit. Since 2019, Mr. Senner has served as a member of the board of directors of Quince Therapeutics, Inc., a publicly held clinical-stage biopharmaceutical company. Mr. Senner holds a B.S. in Finance from Bentley College.

Dana T. Aftab, Ph.D., has served as the Executive Vice President, Research & Development at Exelixis since August 2025. Previously, he served as Executive Vice President, Discovery and Translational Research and Chief Scientific Officer at Exelixis from December 2022 to August 2025, where he led research efforts to drive innovation and expand the company's product candidate pipeline, and as Executive Vice President, Business Operations from February 2016 to December 2022, during which time he oversaw the company's corporate site development and campus operations, including the opening of new laboratory buildings at Exelixis' Alameda campus. Dr. Aftab first joined Exelixis in 1998, starting in Exelixis' Drug Discovery organization, where he led teams that drove the discovery and development of the company's approved medicines, including cabozantinib. In 2007, he moved into the company's clinical development organization, where he led the effort to streamline Exelixis' processes for transitioning drug discovery programs into clinical development, serving as Senior Vice President, Translational Research from 2009 to 2016. Prior to joining Exelixis, Dr. Aftab held senior scientist positions at several biotech start-ups. Dr. Aftab holds B.A. and Ph.D. degrees in pharmacology from the University of California, Santa Barbara and Yale University, respectively, and did his postdoctoral work at the University of California, Berkeley in the field of oncogene signaling.

Patrick J. Haley, has served as the company's Executive Vice President, Commercial since February 2020 and has held positions of progressive commercial leadership since September 2010, serving as Senior Vice President, Commercial from December 2016 to February 2020, Vice President, Commercial from November 2014 to November 2016, Executive Director, Sales & Marketing from September 2013 to October 2014, Senior Director, Marketing from March 2012 to August 2013, and as Director, Marketing from September 2010 to February 2012. Prior to joining Exelixis, from 2007 to 2010, he held positions of increasing responsibility at Genentech, Inc., on the Avastin marketing team, most recently Group Product Manager. Between 2003 and 2007, Mr. Haley served in various sales and marketing roles at Amgen. He served as an analyst at PWC Securities, Lehman Brothers and Accenture from 1998 to 2001. Since October 2024, Mr. Haley has served as a member of the board of directors of NetraMark Holdings Inc., a publicly held generative AI software company focused on clinical trial analytics. Mr. Haley holds a Masters of Business Administration from University of Michigan, Ross School of Business, and a Bachelor of Arts in Art History and Medieval and Renaissance Studies from Duke University.

Brenda J. Hefti, J.D., Ph.D., has served as Senior Vice President and General Counsel since November 2025. Dr. Hefti has held several positions of increasing responsibility at Exelixis since she joined the company in 2013, including serving as Senior Vice President, Intellectual Property and Licensing from 2019 to 2025. From 2010 to 2013, Dr. Hefti served as Assistant Director, Industry Contracts at the University of California, San Francisco (UCSF), where she led negotiations for several strategic partnerships between UCSF and pharmaceutical companies, and worked on research and clinical transactions, patent strategy and licensing. From 2008 to 2010, Dr. Hefti was an Associate at Wilson Sonsini Goodrich & Rosati, LLP, where she advised public and private medical device and biotechnology companies on corporate governance, mergers and acquisitions, public company reporting and private equity and debt financings. Dr. Hefti received her J.D. from the University of California School of Law and is admitted to practice in California and before the U.S. Patent and Trademark Office. She received her Ph.D. in Neuroscience from the University of Wisconsin, Madison, and holds B.A.s in Molecular and Cell Biology and English Literature from the University of California, Berkeley.

Stelios Papadopoulos, Ph.D., a co-founder of Exelixis, has been a director since December 1994 and has served as Chair of the Board since January 1998. Dr. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC in 2006 after six years as an investment banker with the firm, where he focused on the biotechnology and pharmaceutical sectors. Prior to joining Cowen & Co., he spent 13 years as an investment banker at PaineWebber, Incorporated, where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. Earlier, he held equity research roles at Drexel Burnham Lambert and Donaldson, Lufkin & Jenrette. Before coming to Wall Street in 1985, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. Dr. Papadopoulos was a co-founder of Anadys Pharmaceuticals, Inc., a publicly held biopharmaceutical company focused on improving patient care by developing novel medicines for the treatment of hepatitis C, acquired by F. Hoffmann-La Roche Ltd. in 2011. Dr. Papadopoulos served as a member of its board of directors from 2000 to 2011 and as its Chairman in 2011, prior to the acquisition. Dr. Papadopoulos serves as a member of the board of directors of Ovid Therapeutics, Inc. a publicly held biopharmaceutical company focused on developing small-molecule medicines for brain conditions, since 2025, and as co-founder and Chairman of the board of directors of Epikast, Inc., a privately held company focused on providing sales, medical affairs, market access, patient engagement and other services to pharmaceutical companies, since 2023. He previously served as a member of the board of directors of Regulus Therapeutics Inc., a publicly held biopharmaceutical company focused on the development of medicines targeting microRNAs, from 2008 to 2025, and as Chairman from 2013 to 2025, Biogen, Inc., a publicly held biopharmaceutical company focused on the treatment of serious diseases, from 2008 to 2023, and as its Chairman from 2014 to 2023, and Eucrates Biomedical Acquisition Corp., a special purpose acquisition company (SPAC) as its Chairman, from 2020 to 2023. Dr. Papadopoulos was also co-founder and member of the board of directors of Cellzome Inc., a privately held drug discovery company acquired by GSK plc in 2012. Dr. Papadopoulos is a co-founder and Chairman of Fondation Sante, and previously served as a member of the board of visitors of Duke Medicine and a member of the Global Advisory Board of the Duke Institute for Health Innovation. Dr. Papadopoulos holds an M.S. in Physics, a Ph.D. in Biophysics and an M.B.A. in Finance, all from New York University. Other Current Public Company Boards:Ovid Therapeutics Inc., serving on the Audit Committee and Compensation Committee.

Julie Anne Smith has been a director since September 2016. Previously, Ms. Smith served as: Chief Executive Officer and a member of the board of directors of Nuvig Therapeutics, Inc., a privately held biopharmaceutical company focused on recombinant human therapeutics for autoimmune disease, from 2023 to 2024; as President and Chief Executive Officer and member of the board of directors of ESCAPE Bio Inc., a privately held, clinical-stage biopharmaceutical company focused on therapeutics for genetically defined neurodegenerative diseases, from 2018 to 2022; and as President and Chief Executive Officer and member of the board of directors of Nuredis, Inc., a privately held biotechnology company, from 2017 to 2018. Prior to Nuredis, she served as President and Chief Executive Officer of Raptor Pharmaceutical Corp., a publicly held biopharmaceutical company focused on treatments for rare diseases from 2015 until the company's acquisition by Horizon Pharma plc in 2016, where she also served as Executive Vice President and Chief Operating Officer from 2012 to 2014. From 2008 to 2012, Ms. Smith served as Chief Commercial Officer of Enobia Pharmaceuticals prior to the company's acquisition by Alexion Pharmaceuticals, Inc. Previously, Ms. Smith served as Vice President of Commercial at Jazz Pharmaceuticals plc from 2006 to 2008, as Vice President, Global Marketing at Genzyme General from 2001 to 2005, and in operations and business development roles at Novazyme Pharmaceuticals, from 2000 to 2001. Ms. Smith began her industry career at Bristol-Myers Squibb Company in 1996. Ms. Smith has served as a member of the board of directors of Stoke Therapeutics, Inc., a publicly held biotechnology company focused on genetic disease therapeutics, since 2020. Previously, Ms. Smith served as a member of the board of directors of Audentes Therapeutics, Inc., a publicly held, clinical-stage biotechnology company focused on gene therapy products for rare diseases, from 2016 until its acquisition by Astellas Pharma Inc. in 2020, and as a Director on the Health and Emerging Companies Sections of the Biotechnology Innovation Organization (BIO) board. Ms. Smith holds a B.S. in biological and nutritional sciences from Cornell University. Other Current Public Company Boards:Stoke Therapeutics, Inc., serving on the Compensation Committee (Chair) and Nominating & Governance Committee.

Jack L. Wyszomierski has been a director since February 2004. From 2004 to 2009, Mr. Wyszomierski served as the Executive Vice President and Chief Financial Officer of VWR International, LLC, a supplier of laboratory supplies, equipment and supply chain solutions to the global research laboratory industry. From 1982 to 2003, Mr. Wyszomierski held positions of increasing responsibility within the finance group at Schering-Plough Corporation, a health care company, culminating with his appointment as Executive Vice President and Chief Financial Officer in 1996. Prior to joining Schering-Plough, he was responsible for capitalization planning at Joy Manufacturing Company, a producer of mining equipment, and served as a management consultant at Data Resources, Inc. Mr. Wyszomierski has served as a member of the board of directors of XOMA Corporation, a publicly held biotech royalty aggregator, since 2010, and as its Chairman since January 2024, and as a member of the board of directors of SiteOne Landscape Supply, Inc., a publicly held company that distributes landscape supply products, since 2016. Mr. Wyszomierski previously served as a member of the board of directors of: Unigene Laboratories, Inc., a publicly held biopharmaceutical company, from 2010 to 2013; AssuraMed Holding, Inc., a privately held distributor of home healthcare products, from 2011 until its acquisition by Cardinal Health Inc. in 2013; Solenis, Inc., a privately held chemicals producer from 2014 until its acquisition by Platinum Equity in 2021; and Athersys, Inc., a publicly held company engaged in the discovery and development of therapeutic product candidates, from 2010 until 2024. Mr. Wyszomierski holds a M.S. in Industrial Administration and a B.S. in Administration, Management Science and Economics from Carnegie Mellon University. Other Current Public Company Boards:XOMA Corporation (chair), serving on the Audit Committee and the Compensation CommitteeSiteOne Landscape Supply, Inc., serving on the Audit Committee and the Nominating & Corporate Governance Committee (Chair).

Tomas J. Heyman has been a director since May 2023. Since 2025, Mr. Heyman has served as Executive Partner at Bioqube Ventures, a life sciences investment firm, having previously served as Operating Partner from 2020 to 2025. Mr. Heyman was a consultant to Interlaken Therapeutics, Inc., a biotechnology company, and served as its interim Chief Executive Officer, from 2021 to 2024, was President of Johnson & Johnson's Corporate Venture Capital Group, the venture capital arm of Johnson & Johnson, a pharmaceutical and consumer packaged goods company, from 2015 to 2019, and served as Global Head of Business Development for Johnson & Johnson's Pharmaceutical Group from 1992 to 2015. In addition, he served as Managing Director of Janssen Pharmaceutica N.V., an affiliate of Johnson & Johnson (now known as Johnson & Johnson Innovative Medicine), from 2008 to 2016. Mr. Heyman began his career as a member of the legal department of Janssen Pharmaceutica NV in 1982. Mr. Heyman has also served as a member of the board of directors of: Legend Biotech Corporation, a publicly held biotechnology company, since 2022, Primmune Therapeutics, a privately held pharmaceutical company since 2024; and Synox Therapeutics, a privately held biotechnology company, since 2025. Previously, Mr. Heyman served as Non-Executive Chairman of the board of directors of Venatorx, Inc., a privately held pharmaceutical company from 2023 to 2024. Mr. Heyman has also served as a member of the board of directors of: Xilio Therapeutics Inc., a publicly held biotechnology company, from 2022 to 2024; Invivyd, Inc., a publicly held biopharmaceutical company, from 2021 to 2024; OptiNose, Inc., a publicly held specialty pharmaceutical company acquired by Paratek Pharmaceuticals, from 2020 to 2025; Akero Therapeutics Inc., a publicly held biotech company acquired by Novo Nordisk, from 2020 to 2025; and as a member of the Supervisory Board of Crucell NV, a biotechnology company. Mr. Heyman has also served on the board of directors of the International Biomedical Research Alliance, a non-profit organization focused on biomedical research, since 2018, and on the board of directors of Interuniversitair Micro-Electronica Centrum VZW, a Belgian non-profit organization specializing in micro- and nano-electronic research, since 2012. Mr. Heyman holds a Master of Laws from Katholieke Universiteit Leuven. He completed post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in Business Management at the University of Antwerp in Belgium. Other Current Public Company Boards: Legend Biotech Corporation.

Maria C. Freire, Ph.D., has been a director since April 2018. From 2012 to 2021, Dr. Freire served as President and Executive Director of the Foundation for the National Institutes of Health, and as a member of its board of directors, where she supported public-private partnerships advancing research and clinical trials across oncology, neurodegenerative disease, autoimmune disorders and infectious diseases. From 2008 to 2012, she served as President, and a member of the board of directors, of the Albert and Mary Lasker Foundation, which awards the Lasker Awards in basic and clinical science. From 2001 to 2008, Dr. Freire served as President and Chief Executive Officer of the TB Alliance, where she led drug-development efforts, including the advancement of Pretomanid from preclinical to clinical trials; Pretomanid is now approved for treatment of multidrug-resistant tuberculosis (MDR-TB). From 1995 to 2001, Dr. Freire was Director of the Office of Technology Transfer at the National Institutes of Health. Dr. Freire serves on the board of directors of: Biogen Inc., a publicly held biopharmaceutical company focused on the treatment of serious diseases, since 2021, and in February 2026 was elected Chair of the Biogen board of directors, effective following Biogen's 2025 Annual Shareholders Meeting in June 2026; and Alexandria Real Estate Equities, Inc., a publicly held urban office real estate investment trust focused on collaborative life science and technology campuses, since 2012. She has also held national and international leadership roles, including Chair of the Science Board of the U.S. Food and Drug Administration, member of the World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health and member of the United Nations Secretary General's High-Level Panel on Access to Medicines. Dr. Freire is also a member of the National Academy of Medicine and the Council on Foreign Relations, and has received several honors, including the 2017 Gold Stevie Award for Woman of the Year, the U.S. Department of Health and Human Services Secretary's Award for Distinguished Service, the Arthur S. Fleming Award and the Bayh-Dole Award. Dr. Freire holds a Ph.D. in Biophysics from the University of Virginia and a B.S. from the Universidad Peruana Cayetano Heredia in Lima, Peru. Other Current Public Company Boards: Alexandria Real Estate Equities, serving on the Nominating & Corporate Governance Committee and the Science & Technology Committee (Chair); Biogen Inc., (Board Chair elect) serving on the Compensation and Management Development Committee.

George Poste, DVM, Ph.D., FRS, has been a director since August 2004. Since 2009, Dr. Poste has been the Chief Scientist at the Complex Adaptive Systems Initiative and a Regents' Professor and Del E. Webb Professor of Health Innovation at Arizona State University. From 2003 to 2009, Dr. Poste served as the director of the Biodesign Institute at Arizona State University. Dr. Poste has served as the Chief Executive Officer of Health Technology Networks, a consulting company that specializes in the application of genomic technologies and computing in healthcare, since 2000. From 1992 to 1999, he was the Chief Science and Technology Officer and President, R&D, of SmithKline Beecham Corporation, a pharmaceutical company (later merged into GlaxoSmithKline plc). Dr. Poste served on the Defense Science Board of the U.S. Department of Defense from 2001 to 2010 and is a member of other organizations dedicated to advancing defenses against bioweapons and biowarfare. Dr. Poste has served as a member of the board of directors of Caris Life Sciences, a publicly traded medical diagnostics company, since 2009, and as a member of the board of directors of MediSix Therapeutics Pte. Ltd. (Singapore), a privately held immune engineering company focused on cellular therapies, since 2022. Previously, Dr. Poste served as a member of the board of directors of: InanoBio, Inc., a privately held biotechnology company, from 2021 to 2023; Monsanto Company, a publicly held provider of agricultural products and solutions, from 2003 until its acquisition by Bayer Aktiengesellschaft in 2018; Orchid Cellmark, Inc., a publicly held DNA forensics company, from 2000 until its acquisition by the Laboratory Corporation of America in 2009 as non-executive chairman. Dr. Poste is a Fellow of the Royal Society, the UK Academy of Medical Sciences, Hoover Institution, Stanford University, and has been awarded honorary doctorates from several universities. Dr. Poste holds a DVM in veterinary medicine and a Ph.D. in Virology from the University of Bristol, England and holds Board Certification in Pathology from the Royal College of Pathologists. Other Current Public Company Boards:Caris Life Sciences, Inc.

Mary C. Beckerle, Ph.D., has been a director since January 2024. She currently serves as a Distinguished Professor of Biology and Oncological Sciences at the University of Utah. She first joined the faculty of the University of Utah in 1986, where she has held numerous research and leadership roles, and served as Chief Executive Officer of the Huntsman Cancer Institute from 2006 to 2025. Dr. Beckerle has served as a member of the board of directors of: Huntsman Corporation, a publicly held global manufacturer of specialty chemicals, since 2011; Johnson & Johnson, a publicly held diversified healthcare company, since 2015; and Halia Therapeutics, a privately held biopharmaceutical company, since 2026. She has been named a National Association of Corporate Directors (NACD) Corporate Governance Fellow and was a 2018 NACD Directorship 100 Honoree. Dr. Beckerle currently serves on several scientific and advisory boards, including the Medical Advisory Board of the Howard Hughes Medical Institute since 2015, as well as an external advisory board of a National Cancer Institute-designated cancer center at the University of Pennsylvania. Previously, Dr. Beckerle served as a member of the Board of Scientific Advisors of the National Cancer Institute from 2018 to 2022, the External Advisory Board of the Dana-Farber/Harvard Cancer Center from 2013 to 2022, the Board of Directors of the American Association for Cancer Research from 2013 to 2016, the American Cancer Society Council for Extramural Grants from 2008 to 2012 (serving as Chair from 2010 to 2012) and the National Institutes of Health's Advisory Committee to the Director from 2007 to 2010, and from 2024 to 2025, as well as President of the American Society for Cell Biology from 2006 to 2007. She is also an elected member of the National Academy of Sciences, the American Philosophical Society and the American Academy of Arts and Sciences. Dr. Beckerle holds a B.A. in Biology and Psychology (magna cum laude) from Wells College, a Ph.D. in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder and completed her post-doctoral fellowship in Anatomy and Cell Biology at the University of North Carolina at Chapel Hill. Other Current Public Company Boards:Huntsman Corporation, serving on the Nominating and Corporate Governance Committee and Sustainability Committee ;Johnson & Johnson, serving on the Regulatory Compliance & Sustainability Committee and Science & Technology Committee (Chair).

David E. Johnson has been a director since May 2023. Since 2017, Mr. Johnson has served as the Managing Partner and Chief Investment Officer of Caligan Partners LP, an SEC registered investment adviser. Previously, he served as Managing Director at the Carlyle Group, a global private equity, alternative asset management and financial services firm, from 2010 to 2017, and as Vice President in the Principal Investments area at Morgan Stanley, a global financial services and investment management firm, from 2004 to 2010. Prior to joining Morgan Stanley, Mr. Johnson worked at Weiss Asset Management, an investment management firm, from 2003 to 2004. Mr. Johnson has served as a member of the board of directors of Liquidia Corporation, a publicly held biopharmaceutical company, since 2021, and on the board of directors of AMAG Pharmaceuticals, Inc., a publicly held pharmaceutical company specializing in products treating iron deficiency anemia, from 2019 until its acquisition by Covis Group S.a r.l. in 2020. Mr. Johnson also serves as a member of the board of directors of The Children's Scholarship Fund, Inc., a privately funded tuition assistance program, and previously served on the Executive Committee for the Harvard College Fund. Mr. Johnson holds an A.B. and S.M. in Applied Mathematics from Harvard College. Other Current Public Company Boards:Liquidia Corporation, serving on the Audit Committee.

S. Gail Eckhardt, M.D., has been a director since January 2024. Since September 2023, Dr. Eckhardt has served as a tenured Professor and Associate Dean of Experimental Therapeutics at Baylor College of Medicine, where she holds the Albert and Margaret Alkek Foundation Endowed Chair and is also Associate Director of Translational Research at the Dan L. Duncan Comprehensive Cancer Center. Between 2017 and 2023, she was a tenured professor at Dell Medical School at the University of Texas at Austin, where she also served as Chair of the Department of Oncology, Associate Dean of Cancer Programs and inaugural Director of the Livestrong Cancer Institutes. Prior to joining the University of Texas, Dr. Eckhardt was a member of the faculty at the University of Colorado School of Medicine from 1999 to 2017 (receiving tenure in 2001), where she held numerous leadership roles, including Division Head of Medical Oncology, Associate Director for Translational Research at the University of Colorado Comprehensive Cancer Center and Director of the Phase I Program and Fellowship.Dr. Eckhardt has served on the board of directors of Syros Pharmaceuticals, Inc., a publicly held biopharmaceutical company focused on developing frontline treatments for patients with hematologic malignancies, from 2020 until 2024. She is currently on the Scientific Advisory Board (Oncology) of Amgen. Dr. Eckhardt has also served on numerous committees and study sections, including the American Society of Clinical Oncology's Molecular Oncology Task Force and Board of Directors, the U.S. Food and Drug Administration's Oncology Drugs Advisory Committee and the National Cancer Institute's Cancer Centers Study Section and Investigational Drug Steering Committee, as well as external advisory boards of eleven National Cancer Institute designated cancer centers. Dr. Eckhardt is a current member of the National Academies Cancer Policy Forum and was previously a lead mentor in the American Society of Clinical Oncology's Leadership Development Program and a member of the board of directors of the Association of American Cancer Institutes. Dr. Eckhardt holds a B.S. in Chemistry from Stephen F. Austin State University and an M.D. from the University of Texas Medical Branch in Galveston. She completed her internship and residency in Internal Medicine at the University of Virginia Medical School, followed by a post doctoral research fellowship in Experimental and Molecular Medicine at Scripps Research Institute in La Jolla, California, and a fellowship in Medical Oncology at the University of California, San Diego.

Robert L. Oliver, Jr. has been a director since May 2023. From 2010 to 2020, Mr. Oliver served in a variety of senior positions at Otsuka America Pharmaceutical, Inc., a pharmaceutical company and subsidiary of Otsuka Holdings Co. Ltd., including President and Chief Executive Officer from 2016 to 2017, President and Chief Operating Officer from 2014 to 2016, Vice President of Sales and Marketing from 2010 to 2014, and served as Chairman of Otsuka Canada Pharmaceutical, Inc. from 2016 to 2020. Prior to joining Otsuka, he served in a variety of senior positions at Wyeth Pharmaceuticals, a pharmaceutical company, where he also served as Senior Vice President from 2008 to 2010 and Vice President from 2005 to 2008. Mr. Oliver began his career with Johnson & Johnson, a pharmaceutical and consumer packaged goods company, where he held a variety of positions from 1989 to 2005. Mr. Oliver has served as an Executive Advisor of CELLIX Biosciences, a biopharmaceutical company, since 2018, and Hyalo Technologies, LLC, since 2017. Mr. Oliver has served as a member of the board of directors of Neurotez, Inc., a privately held biotechnology company, since 2017, and Hyalo Technologies, LLC, a privately held biotechnology and biopharmaceutical company, since 2017. Previously, he served as a member of the board of directors of PsyBio Therapeutics Corp., a publicly held biotechnology company, from 2021 to 2024, as a member of the board of directors and as Executive Advisor of Medison Canada, an affiliate of Medison Pharma Ltd., from 2018 to 2022, and as a member of the board of directors of Immunomedics, Inc., a publicly held biotechnology company, from January 2017 until its acquisition by Gilead Sciences, Inc. in March 2017. Mr. Oliver serves on the Pharma Board of Advisors at Saint Joseph's University and on the Board of Governors of the Accreditation Council for Medical Affairs. Mr. Oliver holds a B.A. from Rutgers University and an M.B.A. from Saint Joseph's University.